Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

• Published in: European journal of nuclear medicine and molecular imaging Vol. 46; no. 9; pp. 1931 - 1939
• Main Authors: Verhoeff, Sarah R., van Es, Suzanne C., Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G., Oosting, Sjoukje F., Aarntzen, Erik H., Brouwers, Adrienne H., Kwee, Thomas C., Heskamp, Sandra, Hoekstra, Otto S., Verheul, Henk, van der Veldt, Astrid A. M., de Vries, Elisabeth G. E., Boerman, Otto C., van der Graaf, Winette T. A., Oyen, Wim J. G., van Herpen, Carla M. L.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2019; Springer Nature B.V
• Subjects: Cancer; Cardiology; Clear cell-type renal cell carcinoma; Computed tomography; Consortia; Fluorine isotopes; Imaging; Kidney cancer; Lesions; Lungs; Lymph nodes; Lymphatic system; Medicine; Medicine & Public Health; Metastases; Metastasis; Nodes; Nuclear Medicine; Oncology; Oncology – Genitourinary; Original; Original Article; Orthopedics; Positron emission; Positron emission tomography; Prognosis; Radiology; Soft tissues; Tomography; Zirconium isotopes; FDG; CAIX; Clear cell renal cell carcinoma; Imaging; Girentuximab; PET
• ISSN: 1619-7070; 1619-7089
• DOI: 10.1007/s00259-019-04358-9

Purpose The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [ 89 Zr]Zr-DFO-girentuximab-PET/CT and [ 18 F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. Methods Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [ 89 Zr]Zr-DFO-girentuximab-PET/CT and [ 18 F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [ 89 Zr]Zr-DFO-girentuximab or [ 18 F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV max ) were measured. Results A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [ 89 Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62 , p  = 0.001), respectively, and more than CT and [ 18 F]FDG-PET/CT combined (84% (95%CI:79–88, p  < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone. Conclusions The addition of [ 89 Zr]Zr-DFO-girentuximab-PET/CT and [ 18 F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.